bupivacaine - Profile

What are the generic sources for bupivacaine and what is the scope of patent protection?

Bupivacaine is the generic ingredient in seventeen branded drugs marketed by Hengrui Pharma, Pacira Pharms Inc, Innocoll, Innocoll Pharms, Anthea Pharma, Aspiro, Civica, Eugia Pharma, Hikma Pharms, Hospira, Meitheal, Onesource Specialty, Somerset, Intl Medicated, Fresenius Kabi Usa, B Braun Medical, Baxter Hlthcare Corp, Huons, Septodont, Amphastar Pharms Inc, and Heron Theraps Inc, and is included in fifty-two NDAs. There are forty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bupivacaine has thirty-three patent family members in eleven countries.

Summary for bupivacaine

International Patents:	33
US Patents:	41
Tradenames:	17
Applicants:	21
NDAs:	52
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bupivacaine

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bupivacaine

Constraining patent/regulatory exclusivity:

INDICATED TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA IN ADULTS VIA A SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA AND VIA AN ADDUCTOR CANAL BLOCK

Dosage:

INJECTABLE, LIPOSOMAL;INJECTION

Dosage:

SOLUTION;INFILTRATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for BUPIVACAINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXPAREL	Injectable Suspension	bupivacaine	133 mg/10 mL	022496	1	2021-12-28
EXPAREL	Injectable Suspension	bupivacaine	266 mg/20 mL	022496	1	2021-08-20

US Patents and Regulatory Information for bupivacaine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hengrui Pharma	BUPIVACAINE LIPOSOME	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	214348-001	Jul 1, 2024		DISCN	No	No
Hengrui Pharma	BUPIVACAINE LIPOSOME	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	214348-002	Jul 1, 2024		DISCN	No	No
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011		RX	Yes	Yes			Y
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011		RX	Yes	Yes
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011		RX	Yes	Yes			Y
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011		RX	Yes	Yes			Y

Expired US Patents for bupivacaine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021

EU/EMA Drug Approvals for bupivacaine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pacira Ireland Limited	Exparel liposomal	bupivacaine	EMEA/H/C/004586Exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.	Authorised	no	no	no	2020-11-16

International Patents for bupivacaine

Country	Patent Number	Title	Estimated Expiration
United Kingdom	2603047	Manufacturing of bupivacaine multivesicular liposomes
United Kingdom	202404737
European Patent Office	4740937	FABRICATION DE LIPOSOMES MULTIVÉSICULAIRES DE BUPIVACAÏNE (MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES)
Australia	2025208569
China	115666621	具有减少的杂质的持续释放药物递送系统及相关方法 (Sustained release drug delivery systems with reduced impurities and related methods)
European Patent Office	4090353	SYSTÈMES D'ADMINISTRATION DE MÉDICAMENT À LIBÉRATION PROLONGÉE AVEC IMPURETÉS RÉDUITES ET PROCÉDÉS ASSOCIÉS (SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODS)

Bupivacaine: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Bupivacaine, a long-acting local anesthetic, holds significant market relevance in surgical, obstetric, and chronic pain management. Despite mature patent status, ongoing formulations and new delivery systems sustain its revenue. The global market is projected to grow, driven by rising surgical procedures, expanding anesthesia use, and technological innovations. Investment opportunities hinge on licensing deals, formulation improvements, and emerging markets. This report analyzes current market dynamics, forecasted financial trajectories, and strategic considerations for stakeholders.

---

1. Investment Scenario Overview

Market Valuation and Growth Potential

Parameter	Data	Source/Notes
Current global market size	USD 1.2 billion (2022)	[1], [2]
CAGR (2023-2030)	4.3%	[3]
Projected market size (2030)	USD 1.76 billion	Applying CAGR to 2022 figure

Key Investment Drivers

• 360Degree Expansion in Regenerative Medicine: Use of bupivacaine in nerve block techniques, pain management devices, and combined delivery systems.
• Formulation Innovation: Liposomal and sustained-release formulations extend duration of anesthesia, commanding premium pricing.
• Emerging Markets: Increasing healthcare infrastructure in Asia-Pacific and Latin America boost demand.
• Post-COVID Surgical Backlog: Elevated surgical procedures globally induce sustained anesthetic needs.

Risks and Challenges

Risk Factors	Details
Patent Expirations	Limited, but key formulations are nearing patent expiry; generic entry anticipated.
Competition	From other local anesthetics (lidocaine, ropivacaine) and biosimilars.
Regulatory Hurdles	Stringent approval pathways for new formulations and delivery systems.
Supply Chain Disruptions	COVID-related manufacturing and logistics impacts.

---

2. Market Dynamics: Supply, Demand, and Competition

Supply Chain Overview

Element	Description	Key Players
Raw Material Sourcing	Epoxy resin intermediates, sodium hydroxide, local anesthetic APIs.	Global suppliers (e.g., BASF, Lonza)
Manufacturing Locations	US, Europe, India, China.	Pfizer, Hospira, Hikma, Teva
Regulatory Framework	FDA (US), EMA (EU), PMDA (Japan), NMPA (China).	Published guidelines, approvals

Demand Drivers Breakdown

Sector	Contribution to Demand	Trends & Notes
Surgical Anesthesia	45%	Steady growth driven by aging population and surgical volume increases.
Obstetric Anesthesia	20%	Rising birth rates and preference for regional anesthesia.
Chronic Pain Management	15%	Adoption of nerve blocks and outpatient pain control.
Regional/Local Anesthesia in ER Settings	10%	Emergency procedures requiring rapid anesthesia.
Emerging Delivery Technologies	10%	Liposomal and nanotech-based sustained-release formulations.

Competitive Landscape

Company	Market Share (Estimated)	Notable Products	Strategic Focus
Pfizer	35%	Marcaine, Sensorcaine	Formulation innovation, pipeline expansion
Hikma	15%	Bupivacaine HCl injection	Cost-effective generics, new delivery systems
Teva	10%	Bupivacaine formulations	Biosimilars, delivery systems innovation
Others	40%	Various regional/local brands	Focus on emerging markets

Table 1: Competitive Landscape Summary

Attribute	Details
Patent Expiry Dates	Vary by region; majority between 2024 and 2028
R&D Focus	Liposomal formulations, reducing toxicity, combining with adjuvants
Pipelines	Few late-stage biosimilars or reformulations for extended duration release

---

3. Financial Trajectory Forecasts

Revenue Trends (2022–2030)

Year	Estimated Global Revenue	Growth Rate	Notes
2022	USD 1.2 billion	—	Base year
2023	USD 1.25 billion	4.2%	Slight increase, demand from elective surgeries remains stable.
2024	USD 1.30 billion	4.0%	Patent expiries approaching, entry of generics.
2025	USD 1.37 billion	5.0%	Adoption of sustained-release and liposomal forms gains momentum.
2026–2030	USD 1.76 billion (2030 goal)	4.3% CAGR	Market expansion + innovation drives growth.

Segmented Revenue Breakdown

Segment	2022 Revenue	2030 Forecast	CAGR	Comments
Traditional injectable forms	USD 600 million	USD 800 million	4.5%	Stable, but declining proportion due to innovations.
Liposomal/sustained-release	USD 200 million	USD 560 million	15%	Rapid growth driven by premium formulations.
Regional/local products	USD 400 million	USD 400 million	Flat	Mature, saturated markets.

Pricing Dynamics

Factor	Trend	Implication
Patent expiry	Price erosion in generics	Margins squeezed for incumbents
Regulatory approvals for new formulations	Premium pricing for innovations	High initial margins, potential for rapid adoption
Market competition	Price competition in mature markets	Lower prices, focus on differentiated products

---

4. Strategic Investment Opportunities

Opportunity Area	Description	Strategic Considerations
Licensing and Out-licensing	Partner with biotech firms for novel delivery systems.	Risk sharing, access to innovation, faster market entry.
Formulation Innovation	Develop liposomal, depot, or biodegradable delivery forms.	Potential for premium pricing, extended patent life.
Entry into Emerging Markets	Expand distribution in Asia-Pacific, Africa, Latin America.	Lower regulatory barriers, larger patient pools.
Digital and Patient Monitoring Tech	Integration into post-operative pain management platforms.	Adds differentiation, improves compliance.

---

5. Comparative Analysis: Bupivacaine vs. Similar Local Anesthetics

Attribute	Bupivacaine	Lidocaine	Ropivacaine
Duration of Action	2–8 hours (long-acting)	1–2 hours	2–6 hours
Toxicity Profile	Cardiotoxicity at high doses	Lower toxicity, fast onset	Similar to bupivacaine, safer profile
Formulation Variety	Available in liposomal and injectable forms	Primarily injectable	Injectable, liposomal options
Patent Status	Expired or soon-expiring	Expired in most markets	Patent expirations looming

Insight: The longer duration and advanced formulations position bupivacaine as a premium product, especially in outpatient and regional anesthesia.

---

6. Policy and Regulatory Environment

Region	Key Policies	Impact on Market
US (FDA)	Clear pathway for liposomal and sustained-release formulations	Facilitate approval of innovative formulations
EU (EMA)	Emphasis on biosimilar and generic competition	Accelerated biosimilar pathways benefit market entrants
China (NMPA)	Rapid approval processes for domestic innovation	Increased local manufacturing and market penetration

Regulatory landscape influences R&D investment, pricing strategies, and market entry timings.

---

Key Takeaways

• Market growth is steady, with a projected CAGR of ~4.3% through 2030, driven by innovation and expanding global healthcare infrastructure.
• Patent expiries pose a risk but also open opportunities for generics and biosimilars; innovation in formulations offers higher margins.
• Emerging markets will increasingly contribute to revenue, supported by healthcare expansion and lower regulatory barriers.
• Formulation and delivery system innovation—particularly liposomal and sustained-release technologies—are crucial for differentiation and premium pricing.
• Supply chain resilience and regulatory agility are vital amid ongoing geopolitical and pandemic-related disruptions.

---

FAQs

1. What are the primary drivers of growth for bupivacaine markets?

The main drivers include increased surgical volumes, adoption of regional anesthesia techniques, advancements in drug formulations providing longer duration and safety, and expansion into emerging markets.

2. How will patent expiries impact bupivacaine’s market landscape?

Patent expiries around 2024–2028 will lead to increased generic competition, exerting downward pressure on prices but also creating licensing and formulary expansion opportunities for innovators.

3. Are there emerging formulations that could significantly alter financial projections?

Yes. Liposomal bupivacaine (e.g., EXPAREL by Pacira Biosciences) demonstrates extended duration and justifies premium pricing, potentially shaping the 2024–2030 revenue trajectory.

4. What regions are anticipated to see the highest growth in bupivacaine demand?

Asia-Pacific, Latin America, and Africa are expected to experience higher growth rates due to expanding healthcare access and surgical volumes.

5. How does competition from other local anesthetics influence investment decisions?

While lidocaine and ropivacaine offer alternatives, bupivacaine’s longer duration and newer formulations may sustain market share. Strategic investments should focus on innovation and emerging markets to mitigate competition effects.

---

References

[1] MarketsandMarkets, “Local Anesthetics Market,” 2022.
[2] Grand View Research, “Global Local Anesthetics Market,” 2022.
[3] ResearchAndMarkets, “Pharma Market Forecasts,” 2023.